Dr. Joseph A. Odin, MD
Hepatology (Hepatology Physician)
- Medicare participating
At a glance
- Medical school
- Icahn School of Medicine at Mount Sinai (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 357
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: Icahn School of Medicine at Mount Sinai
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hepatology Physician primary
NY license 198140 -
Gastroenterology Physician
NY license 198140 -
Transplant Surgery Physician
NY license 198140
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Morristown Medical Center Morristown, NJ
- Mount Sinai Hospital New York, NY
- Hackensack University Medical Center Hackensack, NJ
- Valley Hospital Paramus, NJ
- Chilton Medical Center Pompton Plains, NJ
Medical groups
- Icahn School of Medicine at Mount Sinai (2,843 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 357
- Services billed
- 574
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 239 | 165 |
| New patient office or other outpatient visit, 45-59 minutes | 67 | 67 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 43 | 23 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 17 | 12 |
| Established patient office or other outpatient visit, 20-29 minutes | 16 | 16 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | 12 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 13 | 13 |
| Insertion of needle into vein for collection of blood sample | 12 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tacrolimus Other prescribers in New York, NY | 236 |
| Ursodiol Other prescribers in New York, NY | 122 |
| Prednisone Other prescribers in New York, NY | 77 |
| Carvedilol Other prescribers in New York, NY | 58 |
| Pantoprazole Sodium Other prescribers in New York, NY | 50 |
| Sirolimus | 48 |
| Amlodipine Besylate Other prescribers in New York, NY | 44 |
| Famotidine Other prescribers in New York, NY | 39 |
| Entecavir | 39 |
| Gabapentin Other prescribers in New York, NY | 29 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 8 payments worth $18,099 in total to this clinician.
| Tanabe Pharma America, Inc. | $13,920 |
|---|---|
| Intercept Pharmaceuticals, Inc. | $3,309 |
| Gilead Sciences, Inc. | $870 |
| Consulting Fee | $18,039 |
|---|---|
| Food and Beverage | $59.98 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Tanabe Pharma America, Inc. Jun 12, 2025 | Consulting Fee | $13,920 |
| Intercept Pharmaceuticals, Inc. Mar 7, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $827 |
| Intercept Pharmaceuticals, Inc. Mar 7, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $827 |
| Intercept Pharmaceuticals, Inc. Mar 7, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $827 |
| Intercept Pharmaceuticals, Inc. Mar 7, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $827 |
| Gilead Sciences, Inc. Nov 19, 2025 | Consulting Fee Epclusa · HCV Company’s description;4233081;VEM US;10012137 | $810 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $46,117 in research payments for these studies, mostly to the institutions running them.
- An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
Gilead Sciences, Inc. - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Gilead Sciences, Inc. - A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or an intolerance to ursodeox…
Gilead Sciences, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.